CANFCan-Fite BioPharmaSigning up patients
Namodenoson Treatment of Advanced Pancreatic Cancer
Pancreatic Adenocarcinoma · Pancreatic Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 20 (planned)
- Started
- Nov 10, 2024
- Main results expected
- Jul 15, 2026
- Fully finished
- Dec 15, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Adverse Events
Measured over: Every 2 weeks, assessed up to 1 year
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Change from baseline
Measured over: Every 2 weeks, assessed up to 1 year
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06387342 · record last updated 2025-01-31 · checked 2026-11-09 15:36 UTC